

## **Full-Life Technologies will present preclinical data of its novel PSMA-targeted RDC program $^{225}\text{Ac-FL-020}$ at the AACR Annual Meeting 2024**

**Shanghai, China, and Heidelberg, Germany - Mar. 11, 2024 - Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company,** today announced that preclinical data of  $^{225}\text{Ac-FL-020}$  (a PSMA-targeted RDC program) will be presented in a Poster Session at the AACR (American Association for Cancer Research) Annual Meeting 2024, which will be held on Apr. 5th to 10th, 2024 in San Diego, CA. The poster will also be published in the online Proceedings of the AACR.

### **Poster Session Presentation Details**

**Title:**  $^{225}\text{Ac-FL-020}$  is a novel PSMA-targeting radionuclide drug conjugate (RDC) with superior in vivo anti-tumor activity

**Session Category:** Experimental and Molecular Therapeutics

**Session Title:** Radiation, Theranostics, Radiotheranostics, Normal Tissue, and Cellular Stress

**Session Date and Time:** Tuesday, Apr 9, 2024, 1:30 PM - 5:00 PM

**Location:** Poster Section 29

**Poster Board Number:** 5

**Published Abstract Number:** 6023

### **About $^{225}\text{Ac-FL-020}$**

$^{225}\text{Ac-FL-020}$  is a novel, potential best-in-class next-generation PSMA-targeting radionuclide drug conjugate (RDC) currently being developed for the treatment of mCRPC and expected to enter global Ph1 clinical studies in H1 2024. Its targeting vector, FL-020, was discovered using Full-Life's proprietary Clear-X™ technology, which enables significant improvement of drug uptake in the tumor while maintaining fast systemic clearance. In pre-clinical models,  $^{225}\text{Ac-FL-020}$  has demonstrated potent anti-tumor activity and a favorable safety profile.

### **About Full-Life Technologies**

Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

### **About AACR**

The American Association for Cancer Research (AACR) was founded in 1907. The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. The AACR has more than 50,000 members residing in 129 countries and territories. Membership includes 256 Fellows of the AACR Academy and 54 Nobel laureates. Through its programs and

services, the AACR fosters research in cancer and related biomedical science; accelerates dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

**Media Contacts:**

Full-Life

Email: [pr@t-full.com](mailto:pr@t-full.com)

Website: [www.full-life.com](http://www.full-life.com)